Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms.

Edgar A SamaniegoEmilee GibsonDaichi NakagawaSantiago Ortega-GutierrezMario ZanatyJorge A RoaPascal JabbourDavid M Hasan

Published in: Stroke and vascular neurology (2019)

The use of the GP IIb/IIIa inhibitors tirofiban and DAPT in this series was safe. Tirofiban and DAPT did not affect platelet count or haemoglobin levels and did not increase rate of symptomatic haemorrhages or thromboembolic complications.

Keyphrases

antiplatelet therapy
acute coronary syndrome
percutaneous coronary intervention
atrial fibrillation
risk factors